Efficient delivery of the Bcl-2 antisense oligonucleotide G3139 via nucleus-targeted aCD33-NKSN nanoparticles

Abdelgawad, 2019, Chitosan nanoparticles: Polyphosphates cross-linking and protein delivery properties, Int. J. Biol. Macromol., 136, 133, 10.1016/j.ijbiomac.2019.06.062 Ban, 2021, Evaluation of Pharmacokinetics and Metabolism of Phosphorothioate Antisense Oligonucleotide G3139 in Rat by Capillary Electrophoresis with Laser-Induced Fluorescence, Nucleic Acid Ther., 31, 316, 10.1089/nat.2020.0922 .,Feng, H.,Jingfang, Z., et al., 2019. A Biomimetic Coordination Nanoplatform for Controlled Encapsulation and Delivery of Drug-Gene Combinations. Angew. Chem. Int. Ed. Engl. 58(26), 8804-8808. https://doi: 10.1002/anie.201903417. Capecchi, 1980, High efficiency transformation by direct microinjection of DNA into cultured mammalian cells, Cell, 22, 479, 10.1016/0092-8674(80)90358-X Cheng, 2017, Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer, Pharm. Res., 34, 310, 10.1007/s11095-016-2063-5 Clark, M.C., Stein, A., CD33 directed bispecific antibodies in acute myeloid leukemia. Best Pract. Res. Clin. Haematol. 33(4),101224. https://doi: 10.1016/j.beha.2020.101224. Del Poeta, G., Bruno, A., Del Principe, M.I., et al., 2008. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. Curr. Cancer Drug Targets. 8, 207–222. https://doi: 10.2174/156800908784293640. Gross, 1999, BCL-2 family members and the mitochondria in apoptosis, Genes Dev., 13, 1899, 10.1101/gad.13.15.1899 Hafezi, S., Rahmani, M., 2021. Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives. Cancers (Basel). 13(6), 1292. https://doi: 10.3390/cancers 13061292. Hate, S.S., Reutzel-Edens, S.M., Taylor, L.S., 2020. Influence of Drug-Silica Electrostatic Interactions on Drug Release from Mesoporous Silica-Based Oral Delivery Systems. Mol Pharm. 17(9), 3435-3446. https://doi: 10.1021/acs.Molpharmaceut.0c00488. Hiom, K., Gellert, M., 1997. A stable RAG1-RAG2-DNA complex that is active in V(D)J cleavage. Cell. 88(1), 65-72. https://doi: 10.1016/s0092-8674(00) 81859-0. Hong, Z.,Ping, P.,,et al., 2007. Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy. J Control Release.119(2),143-52.https://doi: 10.1016/j.jconrel.2006.12.021. Huiying, 2021, A Novel Peptide-Equipped Exosomes Platform for Delivery of Antisense Oligonucleotides, ACS Appl. Mater. Interfaces, 13, 10760, 10.1021/acsami.1c00016 Katas, H., Alpar, H.O., 2006. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release. 115(2), 216-225. https://doi:10.1016/j.jconrel.2006.07.021. Kibria, G., Hatakeyama, H., Ohga, N., et al., 2013. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin alphavbeta3-expressing tumor endothelial cells. Biomaterials. 34(22), 5617-5627. https://doi: 10.1016/j.biomaterials.2013.03.094. Kim, M.Y., Yu, K.R., Kenderian, S.S., et al., 2018. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell. 173(6), 1439-1453. https://doi: 10.1016/j.cell.2018.05.013. Kuang, 2017, The design of peptide-amphiphiles as functional ligands for liposomal anticancer drug and gene delivery, Adv. Drug Deliv. Rev., 110-111, 80, 10.1016/j.addr.2016.08.005 Kumar, A., Hodnett, B.K., Hudson, S., et al., 2020. Modification of the zeta potential of montmorillonite to achieve high active pharmaceutical ingredient nanoparticle loading and stabilization with optimum dissolution properties. Colloids Surf. B Biointerfaces. 193,111120. https://doi: 10.1016/j.colsurfb.2020.111120. Laszlo, 2014, The past and future of CD33 as therapeutic target in acute myeloid leukemia, Blood Rev., 28, 143, 10.1016/j.blre.2014.04.001 Ma, 2019, Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in vitro and in vivo, Biomaterials, 197, 182, 10.1016/j.biomaterials.2018.12.033 Min, 2006, A composite gene delivery system consisting of polyethylenimine and an amphipathic peptide KALA, J. Gene Med., 8, 1425, 10.1002/jgm.973 Moreira, 2006, Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality, Rev. Recent Clin. Trials., 1, 217, 10.2174/157488706778250050 Pan, 2009, Antitumor Activity of G3139 Lipid Nanoparticles (LNPs), Mol. Pharm., 6, 211, 10.1021/mp800146j Peter Szekeres, G., Werner, S., Guttmann, P., et al., 2020. Relating the composition and interface interactions in the hard corona of gold nanoparticles to the induced response mechanisms in living cells. Nanoscale. 12(33),17450-17461. https://doi:10.1039/d0nr03581e. Quirolo, Z.B., Sequeira, M.A., Martins, J.C., et al., 2019. Sequence-Specific DNA Binding by Noncovalent Peptide-Azocyclodextrin Dimer Complex as a Suitable Model for Conformational Fuzziness. Molecules. 24(13), 2508. https://doi:10.3390/molecules24132508. Spugnini, 2011, Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft, J Transl Med, 9 Sun, 2016, Factors influencing the nuclear targeting ability of nuclear localization signals, J. Drug Target., 24, 927, 10.1080/1061186X.2016.1184273 Tang, S.Y., Wei, H., Yu, C.Y., et al., 2021. Peptide-functionalized delivery vehicles for enhanced cancer therapy. Int. J. Pharm. 593, 120141. https://doi: 10.1016/j.ijpharm.2020.120141. Tateshita, 2019, Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine, J. Control. Release, 310, 36, 10.1016/j.jconrel.2019.08.002 Tomek, M., Akiyama, T., Dass, C.R., 2012. Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy. J. Pharm. Pharmacol. 64(12),1695-702. https://doi:10.1111/j.2042-7158.2012.01526.x. Wanlop, W.,Bo, Yu.,Yu, Zheng.,et al., 2009. Efficient delivery of antisense oligode-oxyribonucleotide g3139 by human serum albumin-coated liposomes. Mol Pharm. 6(6),1848-1855. https://doi: 10.1021/mp900150g. Watanabe, 2016, Effect of particle size on their accumulation in an inflammatory lesion in a dextran sulfate sodium (DSS)-induced colitis model, Int. J. Pharm., 509, 118, 10.1016/j.ijpharm.2016.05.043 Willier, S., Rothämel, P., Hastreiter, M., et al., 2021. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. Blood. 137(8),1037-1049. https://doi: 10.1182/blood.2020006 921. Yan, C.,Shi, W.,Gu, J.,et al., 2021. Design of a Novel Nucleus-Targeted NLS-KALA-SA Nanocarrier to Delivery Poorly Water- Soluble Anti-Tumor Drug for Lung Cancer Treatment. J Pharm Sci. 110(6), 2432- 2441. https://doi: 10.1016/ j.xphs.2020.12.034. Yan, 2017, Tat-Tagged and Folate-Modified N -Succinyl-chitosan (Tat-Suc-FA) Self-assembly Nanoparticle for Therapeutic Delivery OGX-011 to A549 Cells, Mol. Pharm., 14, 1898, 10.1021/acs.molpharmaceut.6b01167 Yao, J., Fan, Y., Li, Y., et al., 2013. Strategies on the nuclear-targeted delivery of genes. J. Drug Target. 21(10), 926-939. https://doi: 10.3109/1061186X.2013. 830310. Yuan, M.,Wenting, Z.,Yiding, L.,et al., 2019.Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in vitro and in vivo. Biomaterials.197,182-193.https://doi: 10.1016/j.biomaterials.2018.12.033. Zangemeister-Wittke, 2000, A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells, Clin. Cancer Res., 6, 2547 Zibiao, L.,Xuan, L.,Xiaohong, C.,et al., 2017. Targeted delivery of Bcl-2 conversion gene by MPEG-PCL-PEI-FA cationic copolymer to combat therapeutic resistant cancer. Mater. Sci. Eng. C Mater. Biol. Appl. 76, 66-72. https://doi:10.1016/j.msec.2017.02.163.